KaydedilenlerDerginizi ekleyin

Dergiler / Marmara Medical Journal / 2026 / Volume: 38 Issue: 1

Effect of 6-OHDA growth hormone on the calcium binding proteins located in the bulbus olfactorius in Parkinson model rats

Özlem Kirazlı(MARMARA UNIVERSITY)0000-0002-4342-8205
Hatice Efekan(EASTERN MEDITARRANEAN UNIVERSITY)0000-0002-5848-7697
Mehmet Acinikli(Taksim Training and Research Hospital)
Mesut Öztürk(UNIVERSITY OF HEALTH SCIENCES)0000-0002-6844-4359
Serhat Demir(Kartal Dr. Lütfi Kırdar City Hospital,)0009-0009-4423-614X
Zeynep Büyükyılmaz(Taksim Training and Research Hospital)
Ümit Süleyman Şehirli(MARMARA UNIVERSITY)0000-0001-6261-4567
Sayfa
—
Yayın Tarihi
2025-01-29
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

As a result, the slight increase compared to the control group may be due to the neuroprotective effect of GH.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Parkinson’s disease is the second most common neurodegenerative disease.
📊
Temel Bulgular & Veri:Calretinin can buffer calcium when intracellular calcium levels increase.
💡
Sonuç & Katkı:As a result, the slight increase compared to the control group may be due to the neuroprotective effect of GH.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Parkinson’s disease · Growth hormone · Calretinin

Abstract

Objective: Parkinson’s disease is the second most common neurodegenerative disease. One of the earliest signs is hyposmia which may appear in the premotor period resulting from the alpha-synucleinopathy that affects the neurons along the olfactory pathway. Growth hormone (GH) stimulates cell growth and regeneration. The recovery of neuronal functions may be correlated with the GHs. Calretinin can buffer calcium when intracellular calcium levels increase. This study aims to investigate the effect of GH on calretininpositive neurons in the olfactory bulb of Parkinsonian rats. Materials and Methods: 6-hydroxydopamine (6-OHDA) was injected intracranially. GH (0.15 mg/kg/day) and saline were administered subcutaneously for treatment and control groups respectively. Calretinin staining was performed on the sections and calretininpositive neurons in the lateral olfactory tract were counted. Results: Thickness of the lateral olfactory tract was lesser in the control group. The decrease in the thickness of the tract may be an important sign of hyposmia. The calretinin-positive neurons in the olfactory bulb of the treatment group are more in number when compared with the control group. Conclusion: The decrease in expression of calcium-binding proteins is closely related to neurodegenerative diseases. As a result, the slight increase compared to the control group may be due to the neuroprotective effect of GH.

🔖

Bu Makaleye Atıf Yap

Kirazlı, Ö., Efekan, H., Acinikli, M., Öztürk, M., Demir, S., Büyükyılmaz, Z., Şehirli, Ü. S. (2025). Effect of 6-OHDA growth hormone on the calcium binding proteins located in the bulbus olfactorius in Parkinson model rats. Marmara Medical Journal, Volume: 38 Issue: 1. https://doi.org/10.5472/marumj.1627842

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (46)

  1. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Subjective complaints precede Parkinson disease: the Rotterdam study. Arch Neurol 2006;63:362-5. doi: 10.1001/archneur.63.3. noc50312.
  2. P Soares-da-Silva 1, M P Serrão, M A Vieira-Coelho, M Pestana. Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK1 cells. Br J Pharmacol 1998;123:13-22. doi: 10.1038/ sj.bjp.0701572
  3. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971:367:95-122. doi: 10.1111/j.1365-201x.1971.tb11001.
  4. Emborg ME. Evaluation of animal models of Parkinson’s disease for neuroprotective strategies. J Neurosci Methods 2004;139:121-43. doi: 10.1016/j.jneumeth.2004.08.004.
  5. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987;8:115-31. doi: 10.1210/ edrv-8-2-115
  6. Tannenbaum GS. Growth hormone-releasing factor: direct effects on growth hormone, glucose, and behavior via the brain. Science 1984;226(4673):464-6. doi: 10.1126/science.6436973.
  7. Arce VM, Devesa P, Devesa J. Role of growth hormone (GH) in the treatment on neural diseases: from neuroprotection to neural repair. Neurosci Res 2013;76:179-86. doi: 10.1016/j. neures.2013.03.014
  8. Pan, W, Yu Y, Cain CM, Nyberg F, Couraud PO, Kastin AJ. Permeation of growth hormone across the blood-brain barrier. Endocrinology 2005, 146, 4898-904. doi: 10.1210/ en.2005-0587.
  9. Gustafson K, Hagberg H, B A Bengtsson BA, Brantsing C, Isgaard J. Possible protective role of growth hormone in hypoxia-ischemia in neonatal rats. Pediatr Res 1999;45:318- 23. doi: 10.1203/00006.450.199903000-00005
  10. Jan Frystyk. Exercise and the growth hormone-insulin-like growth factor axis. Med Sci Sports Exerc 2010;42:58-66. doi: 10.1249/MSS.0b013e3181b07d2d
  11. Heredia M, Fuente A, Criado J, Yajeya J, Devesa J, Riolobos A S. Early growth hormone (GH) treatment promotes relevant motor functional improvement after severe frontal cortex lesion in adult rats. Behav Brain Res 2013;247:48-58. doi: 10.1016/j.bbr.2013.03.012.
  12. Li R C, Guo S Z, Raccurt M, et al. Exogenous growth hormone attenuates cognitive deficits induced by intermittent hypoxia in rats. Neuroscience 2011, 196, 237-50.
  13. Kohl Z, Schlachetzki JC, Feldewerth J, et al. Distinct pattern of microgliosis in the olfactory bulb of neurodegenerative proteinopathies. Neural Plast 2017:2017:3851262. doi: 10.1155/2017/3851262.
  14. Lois C, García-Verdugo JM, Alvarez-Buylla A. Chain migration of neuronal precursors. Science 1996;271:978-81. doi: 10.1126/science.271.5251.978
  15. Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J Chronic Dis 1975;28:493-7. doi: 10.1016/0021-9681(75)90058-2.
  16. Hang W, Liu G, Han T, Zhang P, Zhang J. Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein. PLoS One 2015;10:e0119928. doi: 10.1371/ journal.pone.0119928
  17. Schwerk A, Altschüler J, Roch M, et al. Human adiposederived mesenchymal stromal cells increase endogenous neurogenesis in the rat subventricular zone acutely after 6-hydroxydopamine lesioning. Cytotherapy 2015;17:199-214. doi: 10.1016/j.jcyt.2014.09.005. Epub 2014 Oct 24.
  18. Mucignat C, Caretta A. Drug-induced Parkinson’s disease modulates protein kinase A and olfactory marker protein in the mouse olfactory bulb. Behav Brain Funct 2017;13:1. doi: 10.1186/s12993.017.0119-
  19. Fairless R, Williams SK, Diem R. Calcium-binding proteins as determinants of central nervous system neuronal vulnerability to disease. Int J Mol Sci 2019; 20:2146. doi: 10.3390/ ijms20092146
  20. Castro ES, Santos-García D, de Deus Fonticoba T, et al. Causes, and factors related to dopamine agonist withdrawal in Parkinson’s disease. Brain Behav 2016;6: e00453. doi: 10.1002/ brb3.453
  21. Leboucq N, Menjot de Champfleur N, Menjot de Champfleur S, Bonafé A. The olfactory system. Diagn Interv Imaging 2013;94:985-91. doi: 10.1016/j.diii.2013.06.006.
  22. Welge-Lüssen A. Ageing, neurodegeneration, and olfactory and gustatory loss. B-ENT 2009;5 Suppl 13:129-32.
  23. Hawkes CH. Is Parkinson’s disease inherited? Br J Hosp Med 1997;4:130-3.
  24. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th edition. Massachusetts: Academic Press, 2006.
  25. Aberg ND, Brywe K G, Isgaard J. Aspects of growth hormone and insulin-like growth factor-i related to neuroprotection, regeneration, and functional plasticity in the adult brain. Sci World J 2006; 6:53-80. doi: 10.1100/tsw.2006.22
  26. Nagaraja TN, Patel P, Gorski M, et al. In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain. Cerebrospinal Fluid Res 2005;2:5. doi: 10.1186/1743-8454-2-5
  27. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-97. doi: 10.1210/edrv.19.6.0353
  28. Frago LM, Pañeda C, Dickson SL, et al. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-i expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology 2002;143:4113-22. doi: 10.1210/en.2002-220261
  29. Grasso S, Bramanti V, Tomassoni D, et al. Effect of lipoic acid and α‐glyceryl‐phosphoryl‐choline on astroglial cell proliferation and differentiation in primary culture. J Neurosci Res 2014;92:86-94. doi: 10.1002/jnr.23289
  30. Lobie PE, García-Aragón J, Lincoln DT, et al. Localization and ontogeny of growth hormone receptor gene expression in the central nervous system. Dev Brain Res 1993;74:225-33. doi: 10.1016/0165-3806(93)90008-X
  31. Baimbridge KG, Celio MR, Rogers JH. Calcium-binding proteins in the nervous system. Trends Neurosci 1992;15:303- 8. doi: 10.1016/0166-2236(92)90081-I
  32. Grillner S, Hellgren J, Menard A. Mechanisms for selection of basic motor programs – roles for the striatum and pallidum. Trends Neurosci 2005;28:364-70. doi: 10.1016/j. tins.2005.05.004
  33. Fiumelli H, Kiraly M, Ambrus A, et al. Opposite regulation of calbindin and calretinin expression by brain‐derived neurotrophic factor in cortical neurons. J Neurochem 2000;74:1870-7. doi: 10.1046/j.1471-4159.2000.074.1870.x
  34. Schwaller B. Calretinin: from a “simple” Ca2+ buffer to a multifunctional protein implicated in many biological processes. Front Neuroanat 2014;8. doi: 10.3389/ fnana.2014.00003
  35. Tsuboi K, Kimber TA, Shults CW. Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion. Brain Res 2000;866:55-64. doi: 10.1016/S0006-8993(00)02219-8
  36. Ma Y, Zhan M, OuYang L, et al. The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats. Behav Brain Res 2014;266:37-45. doi: 10.1016/j.bbr.2014.02.039
  37. Yi H, Bao X, Tang X. Estrogen modulation of calretinin and BDNF expression in midbrain dopaminergic neurons of ovariectomised mice. J Chem Neuroanat 2016;77:60-7. doi: 10.1016/j.jchemneu.2016.05.005
  38. Mercer A, Sancandi M, Maclatchy A, Lange, S. Brain-Regionspecific differences in protein citrullination/deimination in a pre-motor Parkinson’s disease rat model. Int J Mol Sci 2024; 25: 11168. doi: 10.3390/ijms252011168
  39. Kirazli O, Ozkan M, Verimli U, Gulhan R, Arman A, Sehirli U S. The effect of growth hormone on motor findings and dendrite morphology in an experimental Parkinson’s disease model. Anat Sci Int 2024 10.1007/s12565.024.00790-6. doi. org/10.1007/s12565.024.00790-6 Epub ahead of print.
  40. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987;8:115-31. doi: 10.1210/ edrv-8-2-115
  41. Gustafson K, Hagberg H, B A Bengtsson BA, Brantsing C, Isgaard J. Possible protective role of growth hormone in hypoxia-ischemia in neonatal rats. Pediatr Res 1999;45:318- 23. doi: 10.1203/00006.450.199903000-00005
  42. Jan Frystyk. Exercise and the growth hormone-insulin-like growth factor axis. Med Sci Sports Exerc 2010;42:58-66. doi: 10.1249/MSS.0b013e3181b07d2d
  43. Lois C, García-Verdugo JM, Alvarez-Buylla A. Chain migration of neuronal precursors. Science 1996;271:978-81. doi: 10.1126/science.271.5251.978
  44. Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J Chronic Dis 1975;28:493-7. doi: 10.1016/0021-9681(75)90058-2.
  45. Hang W, Liu G, Han T, Zhang P, Zhang J. Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein. PLoS One 2015;10:e0119928. doi: 10.1371/ journal.pone.0119928
  46. Castro ES, Santos-García D, de Deus Fonticoba T, et al. Causes, and factors related to dopamine agonist withdrawal in Parkinson’s disease. Brain Behav 2016;6: e00453. doi: 10.1002/ brb3.453